Stock listing

Lang & Schwarz:A2DG6B Physiomics PLC Aktie

German listing (Lang & Schwarz) of Physiomics PLC · home listing LSE:PYC

Follow Physiomics PLC into a list and get an email when it puts out news.

Home listing price · LSE:PYC

0.415p GBX (pence) 0.000 (0.0%)

Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, LSE:PYC

Past year +7.8% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
0.380p – 0.415p GBX (pence)Nov 20, 2026
Volume
1.72M sharesNov 20, 2026
Market cap
£1.88M GBPAt the close on Nov 20, 2026 · price × 453.2M shares outstanding
52-week range
0.253p – 0.800p GBX (pence)Lowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
£14,664 GBPMedian day 1.28M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Physiomics PLC logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
LSE:PYC · Home0.415p GBX (pence)0.000 (0.0%)1,724,1760.415p0.415p0.380p0.415pClose on Nov 20, 2026
Frankfurt:RVW1€0.0005 EUR-0.0005 (-50.0%)—€0.0005€0.0005€0.0005€0.0010Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · LSE:PYC · GBX (pence), adjusted for splits

DayCloseChange%OpenHighLowVolume
0.415p0.0000.0%0.415p0.415p0.380p1,724,176
0.415p0.0000.0%0.415p0.415p0.386p2,050,000
0.415p-0.010-2.4%0.415p0.415p0.386p2,050,000
0.425p0.0000.0%0.425p0.425p0.400p487,456
0.425p0.0000.0%0.425p0.429p0.400p3,079,464
0.425p0.0000.0%0.425p0.429p0.403p414,621
0.425p0.0000.0%0.425p0.425p0.403p90,310
0.425p0.0000.0%0.425p0.430p0.400p233,500
0.425p+0.005+1.2%0.420p0.435p0.403p675,951
0.420p+0.010+2.4%0.415p0.435p0.380p459,882
0.410p0.0000.0%0.410p0.430p0.370p2,706,116
0.410p-0.015-3.5%0.415p0.415p0.375p3,083,473
0.425p0.0000.0%0.425p0.425p0.400p1,005,526
0.425p0.0000.0%0.425p0.450p0.403p1,370,323
0.425p0.0000.0%0.425p0.438p0.411p3,261,089
0.425p-0.050-10.5%0.450p0.450p0.400p14,142,077
0.475p0.0000.0%0.475p0.475p0.430p6,902,457
0.475p0.0000.0%0.475p0.475p0.451p595,612
0.475p0.0000.0%0.475p0.475p0.470p116,198
0.475p0.0000.0%0.475p0.475p0.451p200,001
0.475p0.0000.0%0.475p0.500p0.450p195,895
0.475p0.0000.0%0.475p0.500p0.475p34
0.475p0.0000.0%0.475p0.500p0.450p971,692
0.475p0.0000.0%0.475p0.500p0.450p1,134,827
0.475p0.0000.0%0.475p0.500p0.450p2,002,172
0.475p0.0000.0%0.475p0.500p0.450p522,766
0.475p0.0000.0%0.475p0.500p0.453p2,657,632
0.475p0.0000.0%0.475p0.500p0.472p949,829
0.475p0.0000.0%0.475p0.500p0.450p122,004
0.475p-0.050-9.5%0.525p0.525p0.470p8,583,565
0.525p0.0000.0%0.525p0.550p0.503p339,934
0.525p0.0000.0%0.525p0.525p0.503p1,127,154
0.525p0.0000.0%0.525p0.550p0.500p1,401,125
0.525p0.0000.0%0.525p0.533p0.503p1,058,694
0.525p0.0000.0%0.525p0.533p0.500p155,268
0.525p0.0000.0%0.525p0.550p0.500p1,825,068
0.525p0.0000.0%0.525p0.550p0.500p1,556,551
0.525p0.0000.0%0.525p0.550p0.510p281,263
0.525p0.0000.0%0.525p0.550p0.500p1,316,928
0.525p0.0000.0%0.525p0.535p0.500p1,275,272
0.525p0.0000.0%0.525p0.539p0.503p4,953,887
0.525p+0.050+10.5%0.500p0.550p0.500p26,053,755
0.475p-0.035-6.9%0.510p0.520p0.468p7,626,601
0.510p-0.015-2.9%0.525p0.535p0.480p9,347,897
0.525p0.0000.0%0.525p0.525p0.525p1,702,733
0.525p0.0000.0%0.525p0.530p0.500p2,991,992
0.525p0.0000.0%0.525p0.550p0.500p529,252
0.525p0.0000.0%0.525p0.525p0.500p6,910,912
0.525p0.0000.0%0.525p0.550p0.515p1,252,602
0.525p-0.025-4.5%0.550p0.600p0.500p1,602,000
0.550p-0.025-4.3%0.600p0.650p0.520p10,143,141
0.575p+0.050+9.5%0.534p0.600p0.534p8,091,847
0.525p+0.010+1.9%0.515p0.550p0.504p7,441,138
0.515p0.0000.0%0.515p0.515p0.480p1,383
0.515p0.0000.0%0.515p0.515p0.484p481,192
0.515p0.0000.0%0.515p0.515p0.484p521,126
0.515p0.0000.0%0.515p0.550p0.480p1,199,739
0.515p0.0000.0%0.515p0.524p0.480p555,878
0.515p0.0000.0%0.515p0.515p0.511p870,394
0.515p0.0000.0%0.515p0.515p0.480p1,113,072
0.515p0.0000.0%0.515p0.550p0.480p3,210,057
0.515p0.0000.0%0.515p0.524p0.483p2,814,292
0.515p+0.045+9.6%0.470p0.550p0.470p18,228,268
0.470p0.0000.0%0.470p0.475p0.447p1,888,647
0.470p0.0000.0%0.470p0.470p0.469p72,495

Splits

1 split · LSE:PYC · every price before a split is adjusted for it

DayRatioWhat
1-for-100Consolidation
Ticker
Lang & Schwarz:A2DG6B
Asset type
Stock
Sector
Health care
Industry
Diagnostics & research services
Exchange
Lang & Schwarz
Currency
EUR

What changed lately

Latest news

Result of AGM, Issue of Equity & TVR

Nov 5, 2026

Closed 0.41p (0.0%) on Nov 5, 2026

Contract Award

Oct 20, 2026

Closed 0.475p (0.0%) on Oct 20, 2026

Contract Win and Commercial Opportunities

Oct 14, 2026

Closed 0.475p (0.0%) on Oct 14, 2026

Final Results & Notice of AGM

Oct 13, 2026

Closed 0.475p (0.0%) on Oct 13, 2026

Physiomics Awarded New Contract Wins

Sep 10, 2026

Closed 0.55p (-4.3%) on Sep 10, 2026

Physiomics Awarded Multiple New Contracts

Jul 8, 2026

Closed 0.475p (0.0%) on Jul 8, 2026

Appointment of Chief Operating Officer

Jul 1, 2026

Closed 0.475p (0.0%) on Jul 1, 2026

Operations Update

Jun 26, 2026

Closed 0.475p (0.0%) on Jun 26, 2026

All Physiomics PLC news

Physiomics PLC on 6ix

Sector
Health care
Industry
Diagnostics & research services
News releases
34 in the last 12 months · 267 in all · newest Nov 5, 2026 · oldest 2004
Calls
12 calls with a replay · 12 with a transcript · latest Apr 9, 2026
Decks
7 decks · latest Jan 29, 2024

Where Physiomics PLC is listed

ListingExchangeCountryCurrency
LSE:PYC · Home listingLSEUnited KingdomGBX
LS Exchange:A2DG6BLS ExchangeGermanyEUR
Lang & Schwarz:A2DG6B · This pageLang & SchwarzGermanyEUR
Frankfurt:RVW1FrankfurtGermanyEUR
Stuttgart:RVW1StuttgartGermanyEUR

Valuation

EV/sales 1.6× against a median of 4.5×: 4th lowest of 8 Diagnostics & research services companies shown. Statements: Year to Jun 30, 2026 · price Nov 20, 2026

Enterprise value
£1.46M GBP
P/E
Loss
EV/sales
1.6×
EV/EBITDA
Negative EBITDA
Price/book
3.6×
Gross margin
−84.7%
Operating margin
−84.7%
Net margin
−74.1%
Debt to equity
0.0×
Beta
No index for this market yet

Diagnostics & research services: the 10 companies nearest in size, of 302 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Physiomics PLC · LSE:PYCUS$2.46MUS$1.91Mn/a1.6×n/a3.6×−74.1%0.0×n/a
SDS Optic Spolka Akcyjna · NEWCONNECT:SDSUS$3.81MUS$3.57Mn/a13.7×n/a11.8×−269.4%0.0×n/a
genXone SA · NEWCONNECT:GX1US$3.47MUS$2.76Mn/a4.5×18.6×1.9×−67.9%0.0×n/a
Telo Genomics Corp. · TSXV:TELOUS$2.80MUS$2.12Mn/an/an/an/an/an/a0.04
Advanced Biomed Inc. · NASDAQ:ADVBUS$2.73MUS$3.12M0.5×12.2×n/a0.2×n/a0.1×0.35
Innovotech Inc. · TSXV:IOTUS$2.66MUS$2.51Mn/a1.0×n/a1.5×−21.1%0.1×0.39
Qlife Holding AB · OMXSTO:QLIFEUS$2.49MUS$2.88Mn/a34.1×n/a9.6×n/a3.1×n/a
20/20 BioLabs, Inc. · NASDAQ:AIDXUS$2.10M−US$1.01Mn/a−0.5×n/a3.4×−317.8%0.9×1.41
Bluejay Diagnostics, Inc. · NASDAQ:BJDXUS$1.90M−US$5.43Mn/an/an/a0.3×n/a0.0×1.71
Accustem Sciences Inc · OTC:ACUTUS$1.90MUS$1.88Mn/an/an/an/an/an/a0.19
InVitro International · OTC:IVROUS$1.87MUS$644,26029.6×0.8×14.0×1.1×8.2%0.0×0.17
Median of the othersUS$2.57MUS$2.32M15.1×4.5×16.3×1.7×−67.9%0.0×0.35

Team and board

Officers

OfficerRole
Peter SargentCEO
Jesse ThissenCOO & Head of Biometrics
Ian BagnallFinance Director & Company Secretary
Hayley CloseHead of Business Development
Michael WhitlowExecutive Director

Board

DirectorRole
Nicholas TullochNon-Executive Chair
Michael WhitlowExecutive Director

Events

Open Events

Decks

DeckKindSlidesDate
Corporate Update (January 2024)Corporate update7 slidesJan 29, 2024
Physiomics Webinar 30 March 2023Conference19 slidesMar 30, 2023
H1 2021 Earnings PresentationEarnings18 slidesMar 12, 2021
FY2020 Earnings PresentationEarnings17 slidesOct 6, 2020
Biotrinity 2020Conference9 slidesApril 2020
BioTrinity 2019Conference10 slidesApr 30, 2019
BIO-Europe 2008Conference11 slidesNov 19, 2008

Open Decks

Financings

RaiseDateIn US dollars
New Ordinary Shares (WRAP Retail Offer Shares)
Closed: £70,000 raised · £0.005 a share · Winterflood Securities Ltd
Dealers: Winterflood Securities Ltd
Use of proceeds: Grow modelling and biostatistics consulting services, develop personalised dosing tool with DoseMe, and general working capital
Feb 17, 2025US$88,234
Private placement of new ordinary shares
Announced: £430,000 · £0.005 a share · Hybridan LLP
Dealers: Hybridan LLP (lead)
Use of proceeds: Growth of modelling and biostatistics consulting services, personalised medicine tool development, and general working capital
Feb 13, 2025US$538,089

Open Financings · Read by 6ix AI from the company's releases

Financials

Annual, in GBP

Income statement

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue941.2K784.0K543.3K597.4K830.3K702.3K799.1K783.1K512.9K270.5K
Cost of revenue1.74M1.27M1.22M1.18M1.26M1.07M976.2K961.8K770.1K759.7K
Gross profit-797.2K-435.1K-677.4K-581.6K-429.0K-365.8K-177.1K-178.7K-257.2K-489.2K
Research and development211.2K
Selling, general and administrative11.3K11.3K11.0K10.5K10.5K14.0K14.4K
Operating income-797.2K-457.8K-670.8K-573.7K-359.1K-337.0K-177.2K-201.5K-260.4K-489.2K
Depreciation and amortization8.89K9.06K8.95K10.4K11.1K12.4K9.51K8.39K3.15K4.91K
EBITDA-788.3K-448.7K-661.9K-563.3K-348.0K-324.6K-167.6K-193.1K-257.2K-484.3K
Interest expense56603301421106790410
Income before tax-741.1K-457.3K-668.8K-572.0K-359.0K-336.9K-133.7K-200.7K-260.4K-530.4K
Income tax-44.0K-42.0K-59.4K-94.8K-105.8K-121.1K-69.3K-96.7K-77.1K-129.9K
Net income-697.0K-415.3K-609.4K-477.3K-253.1K-215.8K-64.4K-104.0K-183.3K-400.5K
Earnings per share, basic-0.00-0.00-0.00-0.00-0.00-0.00-0.00-0.00-0.00-0.01

Balance sheet

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash and equivalents418.6K461.2K191.1K416.6K687.7K1.04M1.05M405.4K571.9K209.8K
Receivables342.4K363.3K150.9K244.4K410.0K260.7K383.2K103.8K50.4K37.3K
Inventory41.7K-212.1K1-233.1K11
Current assets761.0K875.9K401.4K661.0K1.10M1.30M1.43M674.5K813.2K409.3K
Property, plant and equipment7.76K14.4K15.7K11.5K18.4K5.00K5.83K
Total assets788.6K892.0K422.6K674.4K1.12M1.32M1.45M694.3K818.2K415.2K
Accounts payable85.7K88.5K34.8K18.1K26.8K18.8K27.9K26.5K15.5K23.2K
Current liabilities264.6K199.9K140.1K142.7K140.6K157.6K131.5K86.4K128.2K86.9K
Total debt3.83K7.35K
Total liabilities264.6K199.9K140.1K142.7K140.6K157.6K131.5K86.4K128.2K86.9K
Shareholders' equity524.0K692.2K282.5K531.7K974.8K1.17M1.31M607.9K690.0K328.3K
Shares outstanding345.5M238.2M135.4M97.4M97.4M97.1M73.7M71.9M59.1M51.5M

Cash flow

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations-561.7K-546.1K-548.1K-264.9K-349.3K-32.5K-115.7K-143.8K-169.8K-437.3K
Capital spending-4.43K-3.94K-17.3K-6.63K-9.37K-16.2K-5.09K-21.8K-2.33K-6.80K
Free cash flow-566.2K-550.1K-565.4K-271.5K-358.6K-48.6K-120.8K-165.6K-172.1K-444.1K
Cash from investing-4.43K-3.41K-15.2K-6.22K-9.37K-16.2K-5.09K-22.7K-2.29K-6.65K
Cash from financing523.6K819.7K337.8K2.85K44.2K763.3K763.3K534.2K514.8K
Share buybacks514.8K
Change in cash-42.6K270.2K-225.5K-271.1K-355.8K-4.41K642.5K-166.5K362.1K70.8K

Open Financials

Cap table

Built by 6ix from Physiomics PLC’s releases · as of Feb 17, 2025

Common shares
453,208,718
Fully diluted
453,208,718

Fully diluted

LineShares
Common shares453,208,718

Share count over time

CountShares
Nov 22, 2026453,208,718

Open Cap table

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Hayley CloseHead of Business Development · Since at least May 27, 2026
Ian BagnallFinance Director & Company Secretary · Since at least Oct 20, 2026
Jesse ThissenCOO & Head of Biometrics · Since at least Oct 13, 2026
Michael WhitlowExecutive Director · Since at least Oct 13, 2026
Nicholas TullochNon-Executive Chair · Since at least Apr 29, 2026
Peter SargentCEO · Since at least Apr 29, 2026

Open People

Log in to ask 6ix AI your own questions about Physiomics PLC.